Business Segments

Providing the world’s 7 billion people access to medicine is an opportunity we welcome every day. We have a global workforce of more than 35,000 that is integral in helping us reach patients in more than 165 countries and territories. Our commercial presence is bolstered by our global R&D and manufacturing network, which helps us innovate to satisfy unmet needs. To help ensure our medicines reach the patients who need them, we rely on a broad network of local and global access channels that include physicians, institutions, governments, retailers and wholesalers. Our business is organized in three segments - North America, Europe and Rest of World. This reflects how we manage our global platform – as one business across all product and channel types.

North America

Our North America segment includes our operations in the United States and Canada.

Financial Contributions

In 2016, the North American segment accounted for approximately 51% of Mylan’s net third party sales. Read more about Mylan’s 2016 financial performance.

Highlights

In the United States, the world’s largest pharmaceutical market, Mylan products fill one out of every 13 prescriptions dispensed – brand-name or generic. We offer more than 635 different products to patients in the U.S. spanning virtually every key therapeutic area. We have a manufacturing and R&D footprint that extends across four states plus Puerto Rico. This includes Mylan’s largest oral solid dose facility in Morgantown, West Virginia, which operates roughly one million square feet of manufacturing space under one roof. We also have a long tradition of championing legislation to expand access to high quality medication.

In Canada, Mylan products are sold in eight out of 10 Canadian pharmacies. Additionally, Saint-Hubert, Quebec, is home to one of our 10 global technology-focused development sites.

U.S. Facts

  • More than 22 billion doses of medicine sold every year, at an average price each of just 25 cents
  • More prescriptions filled in 2016 than by Pfizer, GSK, Merck, AstraZeneca, J&J, Sanofi and Lilly combined
  • Nearly 80% of Mylan’s products sold in America are produced at a Mylan U.S. site
  • More generic drug applications approved by FDA over the last two years than any other company
  • In the last year, Mylan filled 1 of every 13 prescriptions in the U.S.


 


Access Channels

We leverage a broad network of local and global access channels that include physicians, institutions, governments, retailers and wholesalers.

These are relationships we've built and nurtured over decades. Because trust goes beyond our global quality standards. It's all about caring for the people helped by what we do. That's how we treat our partners as well. 

When you choose us as a partner, we make the relationship - and the shared value it creates - a priority. After all, it's important to us that you benefit from the work we do together.

If you dispense our difficult-to-manufacture and difficult-to-formulate products, you should know our commitment to producing them is long-term. Whether it's a medication for millions or for a handful of people, our priorities are to meet or exceed industry standards.

Europe

Our Europe segment comprises the company’s operations in countries across the continent, including notable positions in France, Italy, the U.K., Spain, Portugal, Sweden, Netherlands, Austria and Belgium. Our presence continues to grow in several markets in Central and Eastern Europe, including Hungary, Poland, the Czech Republic and Slovakia as well as Romania, Bulgaria and the Balkan States.

Financial Contributions

In 2016, the Europe segment accounted for approximately 27% of Mylan’s net third party sales. Read more about Mylan’s 2016 financial performance.



Highlights

Europe represents the world’s second largest generic pharmaceutical market in terms of value. In France, Mylan stands out among its peers owning the biggest share of the generic segment. In Italy, we have the second highest market share in the generic prescription market in terms of volume and value.

In addition to being a leader in the generics pharmaceutical market throughout Europe, Mylan also holds a strong position in the branded products segment.

Mylan’s manufacturing network in Europe includes 11 facilities in France, Germany, Hungary, Ireland, Italy and Poland where we make a range of oral solid dose, injectable and complex products for markets around the world. Our European R&D presence includes six sites in Germany, Ireland, Italy and the U.K. Our manufacturing and R&D facilities in Europe are critical components of our larger, global network that works to ensure patients have access to the medicines they need.

Key Europe Facts

  • 27 billion doses dispensed across Europe in 2016
  • 1 out of 8 products sold in French pharmacies is a Mylan product
  • Market leader of flu vaccines in Germany and France


 


Access Channels

We leverage a broad network of local and global access channels that include physicians, institutions, governments, retailers and wholesalers.

These are relationships we've built and nurtured over decades. Because trust goes beyond our global quality standards. It's all about caring for the people helped by what we do. That's how we treat our partners as well. 

When you choose us as a partner, we make the relationship - and the shared value it creates - a priority. After all, it's important to us that you benefit from the work we do together.

If you dispense our difficult-to-manufacture and difficult-to-formulate products, you should know our commitment to producing them is long-term. Whether it's a medication for millions or for a handful of people, our priorities are to meet or exceed industry standards.

Rest of World

Our Rest of World segment is made up primarily of our operations in India, Japan and Australia. Also included are our operations in New Zealand and Emerging markets, which includes countries such as Brazil, China, Hong Kong, Malaysia, Taiwan and Thailand, in addition to Russia, South Africa and Turkey.

Financial Contributions

In 2016, the Rest of World segment accounted for approximately 22% of Mylan’s net third party sales. Read more about Mylan’s 2016 financial performance.

Highlights

India is home to nearly half of Mylan’s workforce and approximately half of its manufacturing facilities. Moreover, about half of the company’s regulatory professionals and scientists are based in Hyderabad, where they work in one of Mylan’s global R&D centers. We also have a significant presence in Bangalore, which is where we have many injectables facilities and from which we manage our commercial activities, including our antiretroviral (ARV) and third-party active pharmaceutical ingredients businesses. Mylan’s robust commercial presence in India has made it the fastest growing multinational company in India with strong representation in therapeutic franchises such as hepatitis, oncology and critical care.

Since 2007, Mylan has been instrumental in increasing access to life-saving ARVs and has a majority market share in sub-Saharan African countries such as Zambia, Zimbabwe, Kenya, Nigeria and Cameroon. We are the number 1 provider of antiretroviral medicines in the developing world with a focus on Africa. Key to this achievement has been our success in introducing high quality USFDA-approved and WHO-prequalified products.

Mylan has been among the fastest growing companies in the Japan generics market for the last three years. We also maintain manufacturing capabilities in Japan, which play a key role in supplying our businesses throughout the country. Japan is the world’s second largest pharmaceutical market by value and the fourth largest generic prescription market by volume.

We hold leading positions in the generic pharmaceuticals markets in both Australia and New Zealand, in terms of volume.

With our recent acquisition of Meda, we have accelerated our expansion in attractive emerging markets, such as China, Russia, Southeast Asia and the Middle East.

Key Facts

  • In Emerging markets, Mylan is the ARV market leader with more than 45% of the market share in terms of number of patients
  • Mylan is the number 1 provider of Hepatitis C treatments in Southeast Asia
  • Mylan has the number 1 branded medicine in the symptomatic slow acting drugs for osteoarthritis (SYSADOA) segment in Southeast Asia
  • Mylan holds a leading share of the Hepatitis C market in India
  • Number 1 supplier by volume to Australia's national pharmaceuticals program
  • Produced more than 2 billion doses in Australia in 2016
  • About 1 in 6 prescriptions dispensed in Australia is a Mylan product


 


Access Channels

We leverage a broad network of local and global access channels that include physicians, institutions, governments, retailers and wholesalers.

These are relationships we've built and nurtured over decades. Because trust goes beyond our global quality standards. It's all about caring for the people helped by what we do. That's how we treat our partners as well. 

When you choose us as a partner, we make the relationship - and the shared value it creates - a priority. After all, it's important to us that you benefit from the work we do together.

If you dispense our difficult-to-manufacture and difficult-to-formulate products, you should know our commitment to producing them is long-term. Whether it's a medication for millions or for a handful of people, our priorities are to meet or exceed industry standards.

  1. 0

    Governments

    Our government partners include the Indian National AIDS Control Organisation (NACO) and South Africa’s Department of Health. In India, we’re NACO’s leading supplier of HIV/AIDS medicines and help support its objective to halt and reverse the HIV/AIDS epidemic through integrated prevention, treatment and care and support programs. In South Africa, we’re also one of the leading suppliers of HIV/AIDS medicines.

    We also work with governments around the world through policy initiatives aimed at increasing generic utilization and improving access to high quality medicine.
  2. 0

    Physicians

    Hundreds of Mylan representatives call on thousands of physicians every day. Through these meetings, we’re better able to meet their needs and deliver on our commitment to provide physicians and their patients with access to high quality medicine.


    We also support physicians with initiatives like our Reassurance Program in India. This program helps patients with HIV/AIDS understand their condition and stay connected with their physicians between visits.
  3. 0

    Institutions

    Our institutional customers include a wide range of hospitals, long-term care facilities, correctional facilities, group purchasing organizations, integrated delivery networks and specialty pharmacies. We also work closely with many leading group purchasing organizations to ensure generic and brand name products are available to health care providers within the hospital environment.

    Our unique unit dose package formats include injectables, premixed mini-bags and single-dose and multi-dose vials. These packaging innovations help improve inventory control, reduce dispensing errors and promote the Rights of Medication Administration.


  4. 0

    Mylan On Location™ Program

    Mylan On Location™ is a program that helps organizations better prepare for an emergency on their premises.
  5. 0

    Retailers

    We supply national and international chains as well as independent pharmacies. Our series of educational materials helps pharmacies empower their customers with information and answers about common conditions.
  6. 0

    Wholesalers

    Mylan’s worldwide relationships with wholesalers are vital to ensuring our products reach the people who need them in more than 165 countries and territories.
  7. Pharmacy Benefit Managers
    0

    Pharmacy Benefit Managers

    In the U.S., Mylan also works with pharmacy benefit managers (PBMs) to ensure patients have access to our high quality medicines through their health plans.